Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02623439 · ClinicalTrials.gov registry record · Phase 2
A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
A Phase 2 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02623439 is a Phase 2 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 10 participants.
The verdict
NCT02623439, a Phase 2 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective is to determine overall survival 180 days after transplantation involving HLA-haploidentical stem cell/bone marrow graft, and post-transplant Cy.
Interventions
- DRUG Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-09-21 |
| Est. Completion | 2023-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02623439
The ClinicalTrials.gov registry entry for NCT02623439 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant is the first listed.
NCT02623439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02623439 about?
NCT02623439 is a clinical study titled "A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies". The primary objective is to determine overall survival 180 days after transplantation involving HLA-haploidentical stem cell/bone marrow graft, and post-transplant Cy.
What is the current status of trial NCT02623439?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2012-09-21. Estimated completion is 2023-01-01.
What interventions are being tested in trial NCT02623439?
The interventions under investigation include: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant (DRUG).
Who is sponsoring clinical trial NCT02623439?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.